Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetanus toxin heavy chain, specifically the carboxyl-terminal fragment C (TTFC), is a non-toxic 50 kDa domain of the tetanus neurotoxin produced by Clostridium tetani. It is responsible for binding to polysialogangliosides, such as GD1b and GT1b, on the presynaptic membrane of motor neurons at the neuromuscular junction. Following binding, the heavy chain facilitates the internalization and retrograde axonal transport of the toxin into the central nervous system. Because it contains the primary receptor-binding and immunodominant epitope regions of the toxin without the enzymatic toxicity of the light chain, fragment C is a critical target for both active and passive immunization. Vaccines like the tetanus toxoid and recombinant fragment C formulations target this region to elicit neutralizing antibodies that block toxin-receptor interactions. Additionally, passive immunotherapy using tetanus immune globulin or monoclonal antibodies targets these epitopes to neutralize circulating toxin during active infection. Beyond its role in tetanus, the unique retrograde transport and neuroprotective properties of fragment C make it a valuable carrier vector for delivering therapeutic agents across the blood-brain barrier to target neurodegenerative diseases.
Neutralization of toxin binding to neuronal gangliosides, preventing internalization and retrograde transport of the active light chain.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetanus toxin heavy chain (TTFC).